{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"87.4","value":"246"},{"groupId":"OG001","spread":"73.9","value":"272"},{"groupId":"OG002","spread":"117","value":"343"},{"groupId":"OG003","spread":"50.2","value":"239"},{"groupId":"OG004","spread":"77.3","value":"247"},{"groupId":"OG005","spread":"55.4","value":"224"},{"groupId":"OG006","spread":"75.0","value":"241"},{"groupId":"OG007","spread":"47.6","value":"212"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"85"},{"groupId":"OG005","value":"84"},{"groupId":"OG006","value":"29"},{"groupId":"OG007","value":"124"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"99.6","value":"297"},{"groupId":"OG002","spread":"88.1","value":"305"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"89.5","value":"287"},{"groupId":"OG002","spread":"60.3","value":"291"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"Day 29"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"69.8","value":"250"},{"groupId":"OG001","spread":"108","value":"306"},{"groupId":"OG002","spread":"57.4","value":"294"},{"groupId":"OG003","spread":"69.7","value":"255"},{"groupId":"OG004","spread":"72.0","value":"268"},{"groupId":"OG005","spread":"58.1","value":"241"},{"groupId":"OG006","spread":"93.1","value":"240"},{"groupId":"OG007","spread":"105","value":"249"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"54"},{"groupId":"OG005","value":"46"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"73"}],"units":"Participants"}],"title":"Day 43"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"79.5","value":"266"},{"groupId":"OG001","spread":"24.9","value":"216"},{"groupId":"OG002","spread":"65.6","value":"348"},{"groupId":"OG003","spread":"78.9","value":"252"},{"groupId":"OG004","spread":"66.4","value":"263"},{"groupId":"OG005","spread":"66.4","value":"247"},{"groupId":"OG006","spread":"5.54","value":"237"},{"groupId":"OG007","spread":"57.7","value":"255"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"40"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"30"}],"units":"Participants"}],"title":"Day 85"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"45.4","value":"269"},{"groupId":"OG002","spread":"41.4","value":"339"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"Day 127"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"64.9","value":"304"},{"groupId":"OG001","value":"272"},{"groupId":"OG002","value":"287"},{"groupId":"OG003","value":"235"},{"groupId":"OG004","spread":"90.4","value":"233"},{"groupId":"OG005","spread":"59.3","value":"313"},{"groupId":"OG007","spread":"51.7","value":"245"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"6"}],"units":"Participants"}],"title":"Day 169"}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"85"},{"groupId":"OG005","value":"84"},{"groupId":"OG006","value":"29"},{"groupId":"OG007","value":"124"}],"units":"Participants"}],"description":"Serum concentration at end of infusion (CEOI) of Avelumab is reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with non-small cell lung cancer (NSCLC), first line received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG000","title":"Primary Expansion Cohort: NSCLC, First Line"},{"description":"Participants with colorectal cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG001","title":"Secondary Expansion Cohort: Colorectal Cancer"},{"description":"Participants with castrate-resistant prostate cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG002","title":"Secondary Expansion Cohort: Castrate-resistant Prostate Cancer"},{"description":"Participants with Renal cell carcinoma (Second line) received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG003","title":"Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line)"},{"description":"Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG004","title":"Efficacy Expansion Cohort: Ovarian Cancer"},{"description":"Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG005","title":"Efficacy Expansion Cohort: Urothelial Carcinoma"},{"description":"Participants with gastric and gastroesophageal cancer treated with a first-line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG006","title":"Efficacy Expansion Cohort: GC/GEJC, Third Line"},{"description":"Participants with head and neck squamous cell carcinoma (HNSCC) received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG007","title":"Efficacy Expansion Cohort: HNSCC"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic analysis set was used. Here \"Overall number of participants analyzed\" signifies those who were evaluable for this outcome measure and \"Number analyzed\" signifies those who were evaluable at specified time points. Data was reported for those arms for which end of infusion sample were collected as per planned analysis.","reportingStatus":"POSTED","timeFrame":"At Day 1, 15, 29, 43, 85, 127 and 169","title":"Dose Expansion Phase: Serum Concentration at End of Infusion (CEOI) of Avelumab","type":"SECONDARY","unitOfMeasure":"Microgram per milliliter"}